In this issue:
Biomarker-directed pembrolizumab-based combination for NSCLC
First-line atezolizumab vs. chemotherapy in platinum-ineligible NSCLC
Association of immunotherapy duration with OS in advanced NSCLC
Nivolumab-ipilimumab plus stereotactic radiosurgery for intracranial metastases
Binimetinib + hydroxychloroquine for advanced KRAS-mutant NSCLC
Tissue genotyping ± liquid biopsy for stage IV lung adenocarcinoma workup
Pertuzumab + trastuzumab in HER2-mutated/-amplified lung cancer
Novel fourth-generation TKI for EGFRmutated NSCLC
Increasing tobacco cessation in individuals undergoing lung screening
Impact of PD-L1 expression on EGFRTKI efficacy in EGFR-mutated NSCLC
Please login below to download this issue (PDF)